Vaccines based on mutant CALR and JAK2 and their uses

US12018289B2 · kind B2 · utility

Assignee

• JANSSEN BIOTECH, INC. · US

Inventors

• Ricardo Attar · Lawrenceville, US
• Jason DeHart · San Diego, US
• Selina Khan · Leiden, NL
• Vinod Krishna · Philadelphia, US
• Jenifer LUM · Castro Valley, US
• Christian MAINE · San Diego, US
• Barbara Petronella Sanders · Amsterdam, NL
• Manuel Sepulveda · Princeton Junction, US
• Patrick WILKINSON · Collegeville, US
• Roland Christian ZAHN · Rijnsburg, NL

Key dates

• Filing date: Nov 13, 2020
• Grant date: Jun 25, 2024
• Expiry date: Sep 1, 2041

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2800/50
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Provided are vaccines, polypeptides and polynucleotides based on mutant CALR and JAK2 sequences, vectors, host cells, viruses, and methods of making and using them. The disclosure also provides methods of inducing an immune response and methods of treating, preventing, reducing a risk of onset or delaying the onset of a clinical condition characterized by an expression of JAK2V617F or CALR exon 9 mutant, or both JAK2V617F and CALR exon 9 mutant, wherein the method comprises a plurality of administrations of any of the compositions comprising polynucleotides, polypeptides or vectors disclosed herein.